Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Carolyn A. Foster; Laurence M. Howard; Alain Schweitzer; Elke Persohn; Peter C. Hiestand; Balázs Balatoni; Roland Reuschel; Christian Beerli; Manuela Schwartz; Andreas Billich

doi:10.1124/jpet.107.127183

journal article Nov 01, 2007

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Carolyn A. Foster Laurence M. Howard Alain Schweitzer Elke Persohn Peter C. Hiestand Balázs Balatoni Roland Reuschel Christian Beerli Manuela Schwartz Andreas Billich

The Journal of Pharmacology and Experimental Therapeutics Vol. 323 No. 2 pp. 469-476 · Elsevier BV

View at Publisher Save 10.1124/jpet.107.127183

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

Abbott JN, Rönnbäck L, and Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41–53. 10.1038/nrn1824

[2]

Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G, Hajdu R, Rosenbach M, Keohane CA, Mandala S, et al. (2004) Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279: 52487–52492. 10.1074/jbc.m406512200

[3]

Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, and Foster CA (2007) FTY720 sustains and restores neuronal function in MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74: 307–316. 10.1016/j.brainresbull.2007.06.023

[4]

Baumruker T, Billich A, and Brinkmann V (2007) FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 16: 283–289. 10.1517/13543784.16.3.283

[5]

Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N, and Baumruker T (2003) Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278: 47408–47415. 10.1074/jbc.m307687200

[6]

Brinkmann V, Chen S, Feng L, Pinschewer D, Nikolova Z, and Hof R (2001) FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 33: 530–531. 10.1016/s0041-1345(00)02126-6

[7]

Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453–21457. 10.1074/jbc.c200176200

[8]

Daniel C, Sartory N, Zahn N, Geisslinger G, Radeke HH, and Stein JM (2007) FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol 178: 2458–2468. 10.4049/jimmunol.178.4.2458

[9]

Diaz-Romero J, Vogt G, and Weckbecker G (2001) Coexpression of CD4 and CD8α on rat T-cells in whole blood: a sensitive marker for monitoring T-cell immunosuppressive drugs. J Immunol Methods 254: 1–12. 10.1016/s0022-1759(01)00363-5

[10]

Fernández O, Guerrero M, Mayorga C, MuñozL, Leán A, Luque G, Hervás M, Fernández V, Capdevila A, and de Ramón E (2002) Combination therapy with interferon Beta-1b and azathioprine in secondary progressive multiple sclerosis: a two-year pilot study. J Neurol 249: 1058–1062. 10.1007/s00415-002-0787-0

[11]

Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, and Li X-K (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305: 70–77. 10.1124/jpet.102.045658

[12]

Habicht A, Clarkson MR, Yang J, Henderson J, Brinkmann V, Fernandes S, Jurewicz M, Yuan X, and Sayegh MH (2006) Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol 176: 36–42. 10.4049/jimmunol.176.1.36

[13]

Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, and Fields RD (2006) Astrocytes promote myelination in response to electrical impulses. Neuron 49: 823–832. 10.1016/j.neuron.2006.02.006

[14]

Ishii I, Fukushima N, Ye X, and Chun J (2004) Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73: 321–354. 10.1146/annurev.biochem.73.011303.073731

[15]

Jeffery DR, Chepuri N, Durden D, and Burdette J (2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11: 296–301. 10.1191/1352458505ms1154oa

[16]

Jung CG, Kim HJ, Miron VE, Cook S, Kennedy TE, Foster CA, Antel JP, and Soliven B (2007) Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia, in press. 10.1002/glia.20576

[17]

Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, Proia RL, and Cyster JG (2006) Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 203: 2683–2690. 10.1084/jem.20061289

[18]

Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124–1140. 10.1056/nejmoa052643

[19]

Kataoka H, Sugahara K, Shimano K, Teshima K, Koyama M, Fukunari A, and Chiba K (2005) FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2: 439–448.

[20]

Kharel Y, Lee S, Snyder AH, Sheasley-O’Neill SL, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, et al. (2005) Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 280: 36865–36872. 10.1074/jbc.m506293200

[21]

Kohm AP, Williams JS, Bickford AL, McMahon JS, Chatenoud L, Bach J-F, Bluestone JA, and Miller SD (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174: 4525–4534. 10.4049/jimmunol.174.8.4525

[22]

Lo CG, Xu Y, Proia RL, and Cyster JG (2005) Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med 201: 291–301. 10.1084/jem.20041509

[23]

Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei G-J, Card D, Keohane C, et al. (2002) Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 296: 346–349. 10.1126/science.1070238

[24]

Meno-Tetang GML, Li H, Mis S, Pyszczynski N, Heining P, Lowe P, and Jusko WJ (2006) Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl) ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 34: 1480–1487. 10.1124/dmd.105.009001

[25]

Meno-Tetang GML and Lowe PJ (2005) On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 96: 182–192. 10.1111/j.1742-7843.2005.pto960307.x

[26]

Nikolova Z, Hof A, Baumlin Y, and Hof RP (2000) The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD. Transpl Immunol 8: 115–124. 10.1016/s0966-3274(00)00016-2

[27]

Osinde M, Mullershausen F, and Dev KK (2007) Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 52: 1210–1218. 10.1016/j.neuropharm.2006.11.010

[28]

Payne SG, Oskeritzian CA, Griffiths R, Subramanian P, Barbour SE, Chalfant CE, Milstien S, and Spiegel S (2007) The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109: 1077–1085. 10.1182/blood-2006-03-011437

[29]

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899–910. 10.1056/nejmoa044397

[30]

Rao TS, Lariosa-Willingham KD, Lin F-F, Palfreyman EL, Yu N, Chun J, and Webb M (2003) Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res 990: 182–194. 10.1016/s0006-8993(03)03527-3

[31]

Rouach N, Pébay A, Même W, Cordier J, Ezan P, Etienne E, Giaume C, and Tencé M (2006) S1P inhibits gap junctions in astrocytes: involvement of Gi and Rho GTPase/ROCK. Eur J Neurosci 23: 1453–1464. 10.1111/j.1460-9568.2006.04671.x

[32]

Schubart A, Seabrook T, Rausch M, Gemayel J, Hoyer D, Dev KK, and Mir AK (2007) CNS mediated effects of FTY720 (fingolimod) in EAE. Neurology 68 (Suppl 1): A315.

[33]

Schweitzer A, Fahr A, and Niederberger W (1987) A simple method for the quantitation of 14C-whole-body autoradiograms. Int J Appl Radiat Isot 38: 329–333. 10.1016/0883-2889(87)90019-0

[34]

Talbott JF, Loy DN, Liu Y, Qiu MS, Bunge MB, Rao MS, and Whittemore SR (2005) Endogenous Nkx2.2+/Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. Exp Neurol 192: 11–24. 10.1016/j.expneurol.2004.05.038

[35]

Terai K, Soga T, Takahashi M, Kamohara M, Ohno K, Yatsugi S, Okada M, and Yamaguchi T (2003) Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS. Neuroscience 116: 1053–1062. 10.1016/s0306-4522(02)00791-1

[36]

Tham C-S, Lin F-F, Rao TS, Yu N, and Webb M (2003) Microglial activation state and lysophospholipid acid receptor expression. Int J Dev Neurosci 21: 431–443. 10.1016/j.ijdevneu.2003.09.003

[37]

Toman RE, Payne SG, Watterson KR, Maceyka M, Lee NH, Milstien S, Bigbee JW, and Spiegel S (2004) Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 166: 381–392. 10.1083/jcb.200402016

[38]

Webb M, Tham C-S, Lin F-F, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J, and Rao TS (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153: 108–121. 10.1016/j.jneuroim.2004.04.015

[39]

Yu N, Lariosa-Willingham KD, Lin F-F, Webb M, and Rao TS (2004) Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes. Glia 45: 17–27. 10.1002/glia.10297

[40]

Zemann B, Kinzel B, Müller M, Reuschel R, Mechtcheriakova D, Urtz N, Bornancin F, Baumruker T, and Billich A (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107: 1454–1458. 10.1182/blood-2005-07-2628

Cited By

293

Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration

Rickie Patani, Giles E. Hardingham · 2023

Nature Reviews Neurology

Endothelial S1P 1 Signaling Counteracts Infarct Expansion in Ischemic Stroke

Anja Nitzsche, Marine Poittevin · 2021

Circulation Research

Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process

Azadeh Yazdi, Maryam Ghasemi‐Kasman · 2019

Journal of Neuroscience Research

Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration

Andrew R. Clark, Michael Ohlmeyer · 2019

Pharmacology & Therapeutics

Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis

Paul A. Smith, Cindy Schmid · 2018

Journal of Neuroimmunology

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

Douglas R Jeffery, Kottil W Rammohan · 2016

Expert Review of Neurotherapeutics

FTY720 attenuates excitotoxicity and neuroinflammation

Raffaela Cipriani, Juan Carlos Chara · 2015

Journal of Neuroinflammation

Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (Fingolimod) in multiple sclerosis

Chang Wook Lee, Ji Woong Choi · 2010

Archives of Pharmacal Research

Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices

Veronique E. Miron, Samuel K. Ludwin · 2010

The American Journal of Pathology

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

Jerold Chun, Hans-Peter Hartung · 2010

Clinical Neuropharmacology

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Volker Brinkmann, Andreas Billich · 2010

Nature Reviews Drug Discovery

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

Volker Brinkmann · 2009

British Journal of Pharmacology

Metrics

293

Citations

40

References

Details

Published: Nov 01, 2007
Vol/Issue: 323(2)
Pages: 469-476
License: View

Authors

Cite This Article

Carolyn A. Foster, Laurence M. Howard, Alain Schweitzer, et al. (2007). Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis. The Journal of Pharmacology and Experimental Therapeutics, 323(2), 469-476. https://doi.org/10.1124/jpet.107.127183

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

You May Also Like